Literature DB >> 11474225

Significance of ACE genotypes and medical treatments in childhood focal glomerulosclerosis.

C Hori1, M Hiraoka, N Yoshikawa, K Tsuzuki, Y Yoshida, K Yoshioka, K Fujisawa, H Tsukahara, Y Ohshima, M Mayumi.   

Abstract

BACKGROUND: There is little information on the significance of angiotensin-converting enzyme (ACE) genotypes and medical treatments in children with primary focal segmental glomerulosclerosis (FSGS).
METHODS: A multicenter retrospective study was performed on the role of ACE genotypes and medical treatments in 43 Japanese children with FSGS (20 males and 23 females), including 17 children who progressed to end-stage renal failure during the mean observation period of 6.9 +/- (SD) 5.0 years.
RESULTS: The incidence of the D allele of the ACE gene was higher in the whole group of 43 children with FSGS and in a subgroup of 28 steroid-resistant FSGS children (p < 0.05) than in the 130 children of the healthy control group (0.48, 0.48, and 0.33, respectively). ACE genotypes did not affect renal survival in the whole FSGS group nor in the steroid-resistant subgroup. Among the 28 steroid-resistant children, treatment with ciclosporin was effective in delaying the development of end-stage renal failure (p = 0.044), independently of other treatment regimens.
CONCLUSION: The present study of Japanese children with FSGS showed that the D allele of the ACE gene is associated with the development of FSGS, but not associated with the progression of FSGS which was greatly ameliorated with ciclosporin, irrespective of ACE genotypes. Copyright 2001 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11474225     DOI: 10.1159/000046014

Source DB:  PubMed          Journal:  Nephron        ISSN: 1660-8151            Impact factor:   2.847


  4 in total

1.  ACE gene insertion/deletion polymorphism in childhood idiopathic nephrotic syndrome.

Authors:  Erkin Serdaroglu; Sevgi Mir; Afig Berdeli; Nejat Aksu; Mustafa Bak
Journal:  Pediatr Nephrol       Date:  2005-10-06       Impact factor: 3.714

2.  Novel therapy of focal glomerulosclerosis with mycophenolate and angiotensin blockade.

Authors:  Brenda Montané; Carolyn Abitbol; Jayanthi Chandar; José Strauss; Gastón Zilleruelo
Journal:  Pediatr Nephrol       Date:  2003-06-13       Impact factor: 3.714

3.  Efficacy and Safety of ACE Inhibitor and Angiotensin Receptor Blocker Therapies in Primary Focal Segmental Glomerulosclerosis Treatment: A Systematic Review and Meta-Analysis.

Authors:  Kirk N Campbell; Natali Pennese; Andrea Zaffalon; Barbara Magalhaes; Marina Faiella; Dawn J Caster; Jai Radhakrishnan; Vladimir Tesar; Howard Trachtman
Journal:  Kidney Med       Date:  2022-03-24

4.  Angiotensin-converting enzyme gene polymophism in adult primary focal segmental glomerulosclerosis.

Authors:  Rozita Mohd; Zaimi Abdul Wahab; Rizna Cader; Halim A Gafor; Azizah Md Radzi; Shamsul Azhar Shah; Norella Kong Chiew Tong
Journal:  J Clin Med Res       Date:  2014-05-22
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.